CMI-392 is a dual5-lipoxygeneseinhibitor and platelet-activating factor (PAF) receptor antagonist withIC₅₀s of 100 and 10 nM, respectively.

Topical treatment of CMI-392 in the acute and chronic TPA models result in a significant decrease of ear weight, inflammatory cell infiltration, and histological examination. The ED₅₀for PAF-induced mouse hemoconcentration and arachidonic acid-induced mouse ear edema are 2.2 and 1.8 mg/kg, respectively^[1].

633.15

C₃₁H₃₇ClN₂O₈S

205654-37-1

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.